BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36808002)

  • 1. Predictive value of
    Chen K; Wang J; Li S; Zhou W; Xu W
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):1869-1880. PubMed ID: 36808002
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Li P; Wang X; Xu C; Liu C; Zheng C; Fulham MJ; Feng D; Wang L; Song S; Huang G
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1116-1126. PubMed ID: 31982990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra and peritumoral PET radiomics analysis to predict the pathological response in breast cancer patients receiving neoadjuvant chemotherapy.
    Aksu A; Güç ZG; Küçüker KA; Alacacıoğlu A; Turgut B
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500002. PubMed ID: 38527731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Ferreira M; Lovinfosse P; Hermesse J; Decuypere M; Rousseau C; Lucia F; Schick U; Reinhold C; Robin P; Hatt M; Visvikis D; Bernard C; Leijenaar RTH; Kridelka F; Lambin P; Meyer PE; Hustinx R
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3432-3443. PubMed ID: 33772334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy.
    Antunovic L; De Sanctis R; Cozzi L; Kirienko M; Sagona A; Torrisi R; Tinterri C; Santoro A; Chiti A; Zelic R; Sollini M
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1468-1477. PubMed ID: 30915523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of breast imaging parameters obtained from
    Grapin M; Coutant C; Riedinger JM; Ladoire S; Brunotte F; Cochet A; Humbert O
    Eur J Radiol; 2019 Apr; 113():81-88. PubMed ID: 30927964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Textural features of
    Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
    Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular subtype classification of breast cancer using established radiomic signature models based on
    Liu J; Bian H; Zhang Y; Gao Y; Yin G; Wang Z; Li X; Ma W; Xu W
    Front Biosci (Landmark Ed); 2021 Aug; 26(9):475-484. PubMed ID: 34590460
    [No Abstract]   [Full Text] [Related]  

  • 11. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP; Lima EN; Osório CA; do Socorro Maciel M; Baiocchi G; Bitencourt AG; Fanelli MF; Damascena AS; Soares FA
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of pre- and post-neoadjuvant chemotherapy F-18 FDG PET/CT scans in breast cancer: comparison with MRI.
    Choi EK; Yoo IR; Kim SH; Park SY; O JH; Kang BJ
    Acta Radiol; 2018 Jan; 59(1):41-49. PubMed ID: 28427271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Near-Infrared Diffuse Optical Imaging for Early Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: A Comparative Study Using 18F-FDG PET/CT.
    Ueda S; Yoshizawa N; Shigekawa T; Takeuchi H; Ogura H; Osaki A; Saeki T; Ueda Y; Yamane T; Kuji I; Sakahara H
    J Nucl Med; 2016 Aug; 57(8):1189-95. PubMed ID: 26940765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The accuracy of
    Tian F; Shen G; Deng Y; Diao W; Jia Z
    Eur Radiol; 2017 Nov; 27(11):4786-4796. PubMed ID: 28477166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers from in vivo molecular imaging of breast cancer: pretreatment
    Gallivanone F; Panzeri MM; Canevari C; Losio C; Gianolli L; De Cobelli F; Castiglioni I
    MAGMA; 2017 Aug; 30(4):359-373. PubMed ID: 28246950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics based on
    Ou X; Zhang J; Wang J; Pang F; Wang Y; Wei X; Ma X
    Cancer Med; 2020 Jan; 9(2):496-506. PubMed ID: 31769230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment CT and
    Rishi A; Zhang GG; Yuan Z; Sim AJ; Song EY; Moros EG; Tomaszewski MR; Latifi K; Pimiento JM; Fontaine JP; Mehta R; Harrison LB; Hoffe SE; Frakes JM
    J Med Imaging Radiat Oncol; 2021 Feb; 65(1):102-111. PubMed ID: 33258556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of
    Lee IH; Lee SJ; Lee J; Jung JH; Park HY; Jeong SY; Lee SW; Chae YS
    BMC Cancer; 2020 Nov; 20(1):1106. PubMed ID: 33198673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.